Cell therapy in Taiwan is an emerging treatment, not covered by national health insurance and therefore a self‑pay item; consequently, patients are currently admitted on a “self‑pay treatment” basis.
1. Cancer Treatment: Autologous CIK immune cell therapy, autologous DC dendritic cell therapy, autologous NK cell therapy.
Indications
Autologous CIK immune cell therapy: lung cancer, liver cancer, colorectal cancer, cervical cancer, ovarian cancer, glioblastoma, head and neck cancer, stomach cancer, kidney cancer.
Autologous DC dendritic cell therapy: ovarian cancer, brain cancer, non‑small cell lung cancer, esophageal cancer, stomach cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, renal cell carcinoma, breast cancer.
Autologous NK cell therapy: non‑small cell lung cancer, stomach cancer, esophageal cancer, colorectal cancer, breast cancer.
2. Regenerative Medicine:
Autologous adipose-derived stem cell transplantation for “degenerative arthritis and knee cartilage defects”.
Autologous bone marrow mesenchymal stem cell transplantation for “spinal cord injury”.
Autologous adipose-derived stem cell transplantation for “subcutaneous and soft tissue defects”.
